Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
CA 2429467 A1 · Owner: Mori, Sadao · Inventors: Furusako, Shoji; Mori, Sadao; Shirakawa, Kamon
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Based on a finding that the domain ranging from the 269- to 315-positions of human DC14 represented by SEQ ID NO:1 is a site capable of interacting with another protein, an antibody which specifically recognizes an epitope containing a part of this domain is provided. This antibody can inhibit the interaction between human CD14 and another protein and thus suppress cell activation. Moreover, hybridomas producing the above antibody or its fragment; a peptide containing the amino acids in the domain as specified above; a method of constructing an antibody with the use of this peptide as an immunogen; and a method of screening a remedy for sepsis involving the step of bringing a test …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 28, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 28, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 28, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.